Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales

Antimicrobial Agents and Chemotherapy 2026 Open access

Read full text
Authors: Lucía Sánchez-Peña, Salud Rodríguez-Pallares, Tania Blanco-Martín, Gloria Pérez-Rodríguez, Pablo Aja‐Macaya, Lucía González-Pinto, Inmaculada López-Hernández, Belén Aracil García, Alejandro Beceiro, Germán Bou, Jorge Arca-Suárez
DOI: 10.1128/aac.00195-26
Cited by: 1
References: 29

Abstract

ABSTRACT We evaluated the activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against isogenic Escherichia coli and clinical Enterobacterales isolates producing broad-spectrum β-lactamases. Avibactam and ledaborbactam enhanced ceftibuten activity against transformants producing serine-β-lactamases. Ceftibuten/xeruborbactam was also active against VIM and some IMP producers. All combinations were active against OXA-48- and KPC-producing clinical isolates. Ceftibuten/xeruborbactam also retained activity against VIM-producing clinical strains. Susceptibility rates for MBL producers varied, depending on the CLSI or EUCAST breakpoints applied.

Fields of Study & Subjects

Antibiotic Resistance in Bacteria Infections and bacterial resistance Antibiotics Pharmacokinetics and Efficacy

Publication details

Journal / source
Antimicrobial Agents and Chemotherapy
Publisher
American Society for Microbiology
Volume
70
Issue
7
Pages
e0019526–e0019526
Publication date
29 May 2026
Language
EN